AbCellera Launches Second Phase of Global Headquarters Expansion to Advance Capabilities for Bringing New Medicines from Target to the Clinic
21 Settembre 2022 - 2:00PM
Business Wire
AbCellera (Nasdaq: ABCL) today announced it has launched the
second phase of its global headquarters expansion by breaking
ground on its new facility in Vancouver, Canada. The
380,000-square-foot tech campus will include state-of-the-art lab
and office spaces to support AbCellera’s capabilities in bringing
new antibody-based medicines from target to the clinic. The
expansion will accommodate the growth of AbCellera’s existing 450+
person team and the investments into forward integration of
translational science, process development, and clinical
manufacturing capabilities.
“With our current capabilities, we are able to find optimal
clinical antibody candidates with greater precision and speed,
ultimately helping our partners bring medicines to patients
sooner,” said Murray McCutcheon, Ph.D., SVP, Corporate Development
at AbCellera. “Upon completion of this expansion, AbCellera will
stand alone in providing a fully integrated solution for partners
to bring novel antibody-based medicines from target to the clinic.
For many partners, integration allows them to focus resources on
their core business.”
AbCellera empowers its emerging biopharma partners to advance
discovery programs without having to build the underlying
capabilities, teams, and infrastructure. For its large biopharma
partners, AbCellera’s integrated technologies allow intractable
programs to be unlocked seamlessly within a single platform.
“We are recruiting for positions across the organization and
continue to attract top-tier talent who are excited to do
meaningful work that helps advance innovative new medicines for
patients,” said Matthew Kenning, VP, GMP Manufacturing at
AbCellera. “For experienced process development and clinical
manufacturing professionals, AbCellera represents a unique
opportunity to apply their expertise and integrate clinical
manufacturing as an essential part of the antibody discovery and
development process.”
AbCellera broke ground on the first phase of its global
headquarters in the heart of Vancouver — a 170,000-square-foot
facility at 150 West 4th Avenue being developed in 50/50
partnership with Dayhu — in April 2021, with occupancy expected in
late 2023. The second facility, which is directly adjacent to the
first, is a 210,000-square-foot building at 110 West 4th Avenue.
AbCellera is developing it in a 50/50 partnership with Beedie, with
completion scheduled for 2025. The two facilities are located a
short distance away from the site of AbCellera’s planned
130,000-square-foot clinical manufacturing facility, which was
announced in June 2021.
About AbCellera Biologics Inc. AbCellera is a technology
company that searches, decodes, and analyzes natural immune systems
to find antibodies that its partners can develop into drugs to
prevent and treat disease. AbCellera partners with drug developers
of all sizes, from large pharmaceutical to small biotechnology
companies, empowering them to move quickly, reduce cost, and tackle
the toughest problems in drug development. For more information,
please visit www.abcellera.com.
AbCellera Forward-looking Statements This press release
contains forward-looking statements, including statements made
pursuant to the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995. The forward-looking statements are
based on management’s current beliefs and assumptions and on
information currently available to management. All statements
contained in this release other than statements of historical fact
are forward-looking statements, including statements regarding our
ability to develop, commercialize and achieve market acceptance of
our current and planned products and services, our research and
development efforts, and other matters regarding our business
strategies, use of capital, results of operations and financial
position, and plans and objectives for future operations.
In some cases, you can identify forward-looking statements by
the words “may,” “will,” “could,” “would,” “should,” “expect,”
“intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,”
“project,” “potential,” “continue,” “ongoing” or the negative of
these terms or other comparable terminology, although not all
forward-looking statements contain these words. These statements
involve risks, uncertainties and other factors that may cause
actual results, levels of activity, performance, or achievements to
be materially different from the information expressed or implied
by these forward-looking statements. These risks, uncertainties and
other factors are described under "Risk Factors," "Management's
Discussion and Analysis of Financial Condition and Results of
Operations" and elsewhere in the documents we file with the
Securities and Exchange Commission from time to time. We caution
you that forward-looking statements are based on a combination of
facts and factors currently known by us and our projections of the
future, about which we cannot be certain. As a result, the
forward-looking statements may not prove to be accurate. The
forward-looking statements in this press release represent our
views as of the date hereof. We undertake no obligation to update
any forward-looking statements for any reason, except as required
by law.
Source: AbCellera Biologics Inc.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220921005283/en/
Media: Jessica Yingling, Ph.D.; media@abcellera.com,
+1(236)521-6774 Business Development: Murray McCutcheon, Ph.D.;
bd@abcellera.com, +1(604)559-9005 Investor Relations: Melanie
Solomon; ir@abcellera.com, +1(778)729-9116
Grafico Azioni AbCellera Biologics (NASDAQ:ABCL)
Storico
Da Giu 2024 a Lug 2024
Grafico Azioni AbCellera Biologics (NASDAQ:ABCL)
Storico
Da Lug 2023 a Lug 2024